The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat

Neuropharmacology

Volumn 36, Issue 1, 1997, Pages 93-99

  Stoessl, A J ^a   James, K A ^a   Napier, B J ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

dopamine D1 receptor; dopamine D2 receptor; neurotensin; tardive dyskinesia; vacuous chewing movements

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; DOPAMINE ANTAGONISTS; MALE; MASTICATION; MOTOR ACTIVITY; PYRAZOLES; QUINOLINES; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, NEUROTENSIN; SALICYLAMIDES; STEREOTYPED BEHAVIOR;

EID: 0031052319     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00163-3     Document Type: Article

References (43)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
3. Andersson U., Eckernas S.-A., Hartvig P., Ulin J., Langstrom B., Haggstrom J.-E. Striatal binding of C-11-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J. Neural Transm. 79:1990;215-226.
4. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 196:1977;326-328.
5. Castel M.N., Morino P., Dagerlind A., Hokfelt T. Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment. Eur. J. Neurosci. 6:1994;646-656.
6. Castel M.N., Morino P., Frey P., Terenius L., Hokfelt T. Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain. Neuroscience. 55:1993;833-847.
7. DeQuidt M.E., Emson P.C. Neurotensin facilitates dopamine release in vitro from rat striatal slices. Brain Res. 274:1983;376-380.
8. Diana M., Collu M., Mura A., Gessa G.L. Haloperidol-induced vacuous chewing in rats: suppression by a-methyl-tyrosine. Eur. J. Pharmacol. 211:1992;415-419.
9. Doucet J.-P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.-S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of FosB-like protein(s) in the striatum. Eur. J. Neurosci. 8:1996;365-381.
10. Fibiger H.C., Lloyd K.G. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci. 7:1984;462-464.
11. Govoni S., Hong J.S., Yang H.-Y.T., Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J. Pharmacol. Exp. Ther. 215:1980;413-417.
12. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.-C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., Pelaprat D., Labbe-Jullie C., Mazella J., Soubrie P., Maffrand J.-P., Rostene W., Kitabgi P., Le Fur G. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. natn. Acad. Sci. U.S.A. 90:1993;65-69.
13. Gunne L.M., Andersson U., Bondesson U., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
14. Iversen S.D., Howells R.B., Hughes R.P. Behavioral consequences of long-term treatment with neuroleptic drugs. Adv. Biochem. Psychopharmacol. 24:1980;305-313.
15. Jiang L.H., Kassar R.J., Altar C.A., Wang R.Y. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists. J. Pharmacol. Exp. Ther. 253:1990;1198-1205.
16. Jicha J.D., Salomone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral stratium dopamine depletion: possible relation to Parkinsonian symptoms. J. Neurosci. 11:1991;3822-3829.
17. Kelley A.E., Bakshi V.P., Delfs J.M., Lang C.G. Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology. 99:1989;542-549.
18. Kilts C.D., Anderson C.M., Bissette G., Ely T.D., Nemeroff C.B. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem. Pharmacol. 37:1988;1547-1554.
19. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J. Neural Transm. 75:1989;1-10.
20. Koshikawa N., Aoki S., Hiruta M., Tomiyama K., Kobayashi M., Tsuboi Y., Iawata K., Sumino R., Stephenson J.D. Effects of intrastriatal injections of selective dopamine D-1 and D-2 agonists on jaw movements of rats. Eur. J. Pharmacol. 163:1989;227-236.
21. Letter A.A., Matsuda L.A., Merchant K.M., Gibb J.W., Hanson G.R. Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Brain Res. 422:1987;200-203.
22. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12:1992;652-663.
23. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic halperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmacol. Exp. Ther. 271:1994;460-471.
24. Murray A.M., Waddington J.L. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur. J. Pharmacol. 160:1989;377-384.
25. Parent A., Hazrati L.-N. Functional anatony of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry Brain Res. Rev. 20:1995;128-154.
26. Rajakumar N., Rushlow W.J., Naus C.C.G., Stoessl J., Flumerfelt B.A. Effects of chronic neuroleptic treatment on gene expression in the rat striatum as revealed by differential display. Soc. Neurosci. Abstr. 21:1995;1426.
27. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci. 33:1983;2479-2482.
28. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats. Life Sci. 39:1986;29-35.
29. Rupniak N.M.J., Jenner P., Marsden C.D. Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats. Psychopharmacology. 79:1983;226-230.
30. Rupniak N.M.J., Jenner P., Marsden C.D. Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology. 85:1985;71-79.
31. Salamone J.D., Johnson C.J., McCullough L.D., Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology. 102:1990;529-534.
32. Salamone J.D., Lalies M.D., Channell S.L., Iversen S.D. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology. 88:1986;467-471.
33. Steinpreis R.E., Baskin P., Salamone J.D. Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology. 111:1993;99-105.
34. Stoessl A.J. Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology. 34:1995;457-462.
35. Stoessl A.J., Dourish C.T., Iversen S.D. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective D1 and D2 receptor antagonists. Psychopharmacology. 98:1989;372-379.
36. Stoessl A.J., Szczutkowski E. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. Brain Res. 558:1991;289-295.
37. Tarsy D., Baldessarini R.J. Pharmacologically induced behavioural supersensitivity to apomorphine. Nature New Biol. 245:1973;262-263.
38. Torocsik A., Rakovska A., Gorcs T., Vizi E.S. Effect of neurotensin and immunoneutralization with antineurotensin serum on dopaminergic-cholinergic interaction in the striatum. Brain Res. 612:1993;306-312.
39. Trugman J.M., Leadbetter R., Zalis M.E., Burgdorf R.O., Wooten G.F. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Movement Disord. 9:1994;441-446.
40. Uhl G.R., Kuhar M.J. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature. 309:1984;350-352.
41. Van Kampen J., Frydryszak H., Stoessl A.J. Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. Eur. J. Pharmacol. 298:1996;7-15.
42. Waddington J.L., Cross A.J., Gamble S.J., Bourne R.C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science. 220:1983;530-532.
43. Yeghiayan S.K., Kelley A.E. Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacol. Biochem. Behav. 52:1995;493-501.